1-cyclopentyl-3-ethyl-6-(3-ethoxy-pyridin-4-yl)-pyrazolo[3,4-d]pyrimidin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-cyclopentyl-3-ethyl-6-(3-ethoxy-pyridin-4-yl)-pyrazolo[3,4-d]pyrimidin-4-one
• 英文别名: 1-cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin-4-one；1-cyclopentyl-6-(3-ethoxypyridin-4-yl)-3-ethyl-2H-pyrazolo[3,4-d]pyrimidin-4-one
• 化学式: C₁₉H₂₃N₅O₂
• 分子量: 353.424
• InChiKey: VSLMKZXLBKMQKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  79.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  西地那非 、 4-phenylmethylamino-6-chloro-2-(1-imidazolyl)-quinazoline 、 4-phenylmethylamino-6-chloro-2-(pyridin-3-yl)quinazoline 、 、 1-cyclopentyl-3-ethyl-6-(3-ethoxy-pyridin-4-yl)-pyrazolo[3,4-d]pyrimidin-4-one 生成 6-(3-butan-2-yloxypyridin-4-yl)-1-cyclopentyl-3-ethyl-2H-pyrazolo[3,4-d]pyrimidin-4-one
  参考文献：
  名称：

  cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction

  摘要：

  通过吸入cGMP PDE 5抑制剂治疗性功能障碍，特别是5-[2-乙氧基-5-(4-甲基哌嗪磺酰基)苯基]-1-甲基-3-正丙基-1,6-二氢-7H-吡唑并[4,3-d]嘧啶-7-酮，4-苯甲氨基-6-氯-2-(1-咪唑基)喹唑啉，4-苯甲氨基-6-氯-2-(3-吡啶基)喹唑啉，1,3-二甲基-6-(2-丙氧基-5-甲磺酰胺基苯基)-1,5-二氢-吡唑并[3,4-d]嘧啶-4-酮或1-环戊基-3-乙基-6-(3-乙氧基-4-吡啶基)-吡唑并[3,4-d]嘧啶-4-酮。

  公开号：

  US20040214831A1
• 作为产物：
  描述：

  1-cyclopentyl-3-ethyl-6-(3-ethoxy-pyridin-4-yl)pyrazolo[3,4-d]pyrimidin-4-amine 以70%的产率得到1-cyclopentyl-3-ethyl-6-(3-ethoxy-pyridin-4-yl)-pyrazolo[3,4-d]pyrimidin-4-one
  参考文献：
  名称：

  6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and

  摘要：

  新型6-杂环基嘧啶并[3,4-d]嘧啶-4-酮，用于治疗心血管疾病，通过将5-氨基-1H-嘧啶-4-甲酰胺与杂环基羰基或将5-氨基-1H-嘧啶-4-碳腈与杂环基羧酰胺反应制备，随后对所得的4-氨基-6-杂环基嘧啶并[3,4-d]嘧啶进行重氮化和水解。

  公开号：

  US05294612A1

文献信息

• Drugs for incontinence
  申请人：——

  公开号：US20030203899A1

  公开（公告）日：2003-10-30

  Use in the incontinence of one or more of the following classes of drugs selected from the following: B) salified and non salified nitric oxide-donor drugs, of formula: A-X 1 —N(O) z , B′) nitrate salts of drugs used for the incontinence, and which do not contain in the molecule a nitric oxide donor group; C) organic or inorganic salts of compounds inhibiting phosphodiesterases.

  在选择的以下药物类别中使用一种或多种药物来治疗尿失禁：B) 含盐和不含盐的一氧化氮供体药物，化学式为：A-X1—N(O)z，B′) 用于治疗尿失禁的硝酸盐药物，且分子中不含一氧化氮供体基团；C) 抑制磷酸二酯酶的有机或无机盐化合物。
• NOVEL SALT 628
  申请人：Briggner Lars-Erik

  公开号：US20100216843A1

  公开（公告）日：2010-08-26

  6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 4-methylbenzenesulfonate and a novel crystalline form thereof are disclosed together with processes for preparing such salt and form, pharmaceutical compositions comprising such a salt and form, and the methods of treatment using such a salt and form.

  6-甲基-5-(1-甲基-1H-吡唑-5-基)-N-[5-(甲磺酰基)吡啶-2-基]甲基}-2-氧代-1-[3-(三氟甲基)苯基]-1,2-二氢吡啶-3-羧酰胺 4-甲基苯磺酸盐及其一种新的结晶形式，以及制备这种盐和形式的方法，包含这种盐和形式的药物组合物，以及使用这种盐和形式进行治疗的方法。
• cGMP PDE 5 Inhibitors for inhalation in the treatment of sexual dysfunction
  申请人：——

  公开号：US20010055570A1

  公开（公告）日：2001-12-27

  Treatment of sexual dysfunction by inhalation of a cGMP PDE 5 inhibitor, especially 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 4-phenylmethylamino-6-chloro-2-(1-imidazolyl) quinazoline, 4-phenylmethylamino-6-chloro-2-(3-pyridyl) quinazoline, 1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one or 1-cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin-4-one.

  通过吸入cGMP PDE 5抑制剂治疗性功能障碍，特别是5-[2-乙氧基-5-(4-甲基哌嗪磺酰基)苯基]-1-甲基-3-正丙基-1,6-二氢-7H-吡唑并[4,3-d]嘧啶-7-酮、4-苯甲基氨基-6-氯-2-(1-咪唑基)喹唑啉、4-苯甲基氨基-6-氯-2-(3-吡啶基)喹唑啉、1,3-二甲基-6-(2-丙氧基-5-甲烷磺酰胺基苯基)-1,5-二氢-吡唑并[3,4-d]嘧啶-4-酮或1-环戊基-3-乙基-6-(3-乙氧基-4-吡啶基)-吡唑并[3,4-d]嘧啶-4-酮。
• New Combination 665
  申请人：Cadogan Elaine Bridget

  公开号：US20080242649A1

  公开（公告）日：2008-10-02

  The invention provides a pharmaceutical product comprising a first active ingredient which is N—[2-(Diethylamino)ethyl]-N-(2-[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist which is Aclidinium bromide, Glycopyrrolate, Oxitropium bromide, Pirenzepine, telenzepine, Tiotropium bromide, 3(R)—(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide, 3(R)—1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane bromide or (3R)—3-[(2S)—2-cyclopentyl-2-hydroxy-2-thien-2-ylacetoxy]-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]actane bromide; a p38 inhibitor; a PDE inhibitor; a PPARγ agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease.

  本发明提供了一种药物产品，其中包括第一活性成分，该成分为N-[2-(二乙氨基)乙基]-N-(2-[2-(4-羟基-2-氧代-2,3-二氢-1,3-苯并噻唑-7-基)乙基]氨基}乙基)-3-[2-(1-萘基)乙氧基]丙酰胺或其盐，并且包括第二活性成分，所述第二活性成分选自：非类固醇糖皮质激素受体（GR受体）激动剂；抗氧化剂；CCR1拮抗剂；趋化因子拮抗剂（非CCR1）；皮质类固醇；CRTh2拮抗剂；DP1拮抗剂；组蛋白去乙酰化酶诱导剂；IKK2抑制剂；COX抑制剂；脂氧合酶抑制剂；白三烯受体拮抗剂；MPO抑制剂；Aclidinium溴化物、Glycopyrrolate、Oxitropium溴化物、Pirenzepine、telenzepine、Tiotropium溴化物、3(R)-（2-羟基-2,2-二硫基-2-乙酰氧基）-1-(3-苯氧基丙基)-1-氮杂双环[2.2.2]辛烷溴化物、3(R)-1-苯乙基-3-(9H-黄酮-9-羧酰氧基)-1-氮杂双环[2.2.2]辛烷溴化物或（3R）-3-[(2S)-2-环戊基-2-羟基-2-噻唑基乙氧基]-1-(2-苯氧基乙基)-1-氮杂双环[2.2.2]辛烷溴化物；p38抑制剂；PDE抑制剂；PPARγ激动剂；蛋白酶抑制剂；他汀类药物；血栓素拮抗剂；血管扩张剂；或ENAC阻滞剂（上皮钠通道阻滞剂），以及其在呼吸系统疾病治疗中的应用。
• Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone
  申请人：Cadogan Elaine Bridget

  公开号：US20100029732A1

  公开（公告）日：2010-02-04

  The invention provides a pharmaceutical product comprising a first active ingredient which is N-[2-(Diethylamino)ethyl]-N-(2-[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propan amide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor)=Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist which is Aclidinium bromide, Glycopyrrolate, Oxitropium bromide, Pirenzepine, telenzepine, Tiotropium bromide, 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azo-niabicyclo[2.2.2]octane bromide, 3(R)- 1 -phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane bromide or (3R)-3-[(2S)-2-cyclopentyl-2-hydroxy-2-thien-2-ylacetoxy]-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]actane bromide; a p38 inhibitor; a PDE inhibitor; a PPARy agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease.

  该发明提供了一种药物产品，包括第一活性成分为N-[2-(二乙氨基)乙基]-N-(2-[2-(4-羟基-2-氧代-2,3-二氢-1,3-苯并噻唑-7-基)乙基]氨基}乙基)-3-[2-(1-萘基)乙氧基]丙酰胺或其盐，和第二活性成分从以下中选择：非甾体型糖皮质激素受体（GR受体）=激动剂；抗氧化剂；CCR1拮抗剂；趋化因子拮抗剂（非CCR1）；类固醇；CRTh2拮抗剂；DP1拮抗剂；组蛋白去乙酰化酶诱导剂；IKK2抑制剂；COX抑制剂；脂氧合酶抑制剂；白三烯受体拮抗剂；MPO抑制剂；Aclidinium溴化物，Glycopyrrolate，Oxitropium溴化物，Pirenzepine，telenzepine，Tiotropium溴化物，3(R)-(2-羟基-2,2-二噻吩-2-乙氧基)-1-(3-苯氧基丙基)-1-氮杂双环[2.2.2]辛烷溴化物，3(R)-1-苯乙基-3-(9H-黄酮-9-羰基氧基)-1-氮杂双环[2.2.2]辛烷溴化物或(3R)-3-[(2S)-2-环戊基-2-羟基-2-噻吩-2-乙氧基]-1-(2-苯氧基乙基)-1-氮杂双环[2.2.2]辛烷溴化物；p38抑制剂；PDE抑制剂；PPARy激动剂；蛋白酶抑制剂；他汀类药物；血栓素受体拮抗剂；血管扩张剂；或ENAC阻滞剂（上皮钠通道阻滞剂），以及其在呼吸道疾病治疗中的应用。